Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

Peer Review reports

Original Submission
26 Nov 2021	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
22 Dec 2021	Reviewed	Reviewer Report
26 Dec 2021	Reviewed	Reviewer Report
18 Jan 2022	Author responded	Author comments - Sameer R. Ghate
Resubmission - Version 3
18 Jan 2022	Submitted	Manuscript version 3
31 Jan 2022	Author responded	Author comments - Sameer R. Ghate
Resubmission - Version 4
31 Jan 2022	Submitted	Manuscript version 4
9 Feb 2022	Author responded	Author comments - Sameer R. Ghate
Resubmission - Version 5
9 Feb 2022	Submitted	Manuscript version 5
18 Feb 2022	Reviewed	Reviewer Report
Resubmission - Version 6
	Submitted	Manuscript version 6
Publishing
21 Feb 2022	Editorially accepted
11 Mar 2022	Article published	10.1186/s12894-022-00979-9

Back to article page